Amoéba is a greentech based in France, which aims to become a major player in treating microbiological risk in the crop protection and cosmetic sectors. Based on the natural properties of a unique, exclusively patented microorganism, its biological solutions offer a viable alternative to the chemical products widely used in the industry today.

P&S Intelligence’s report noted that the global biocontrol agents market was worth c $4.9bn in 2021 and predicted it would increase to $13.6bn by 2030. According to McKinsey, the global skincare market was $200bn in 2022 and is expected to expand at a CAGR of 6% from 2022 to 2027. There are clear trends towards natural ingredients and premium products, with McKinsey forecasting that the premium end of the market should grow at an 8% CAGR, compared with 5% for the mass market and 6% for the global market. This trend should represent a significant tailwind to any Amoéba product sourced from a natural spring in the south of France.